These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 20419051)

  • 1. Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway.
    Zeng LH; Rensing NR; Wong M
    Mol Cell Pharmacol; 2009 Jan; 1(3):124-129. PubMed ID: 20419051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
    Wong M
    Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.
    McDaniel SS; Wong M
    Neurosci Lett; 2011 Jun; 497(3):231-9. PubMed ID: 21354266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy.
    Zeng LH; Rensing NR; Wong M
    J Neurosci; 2009 May; 29(21):6964-72. PubMed ID: 19474323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.
    Ryther RC; Wong M
    Curr Neurol Neurosci Rep; 2012 Aug; 12(4):410-8. PubMed ID: 22544534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
    Rensing N; Han L; Wong M
    Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of mTOR inhibitors in epilepsy treatment.
    Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
    Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the mTOR signaling pathway in epilepsy.
    Meng XF; Yu JT; Song JH; Chi S; Tan L
    J Neurol Sci; 2013 Sep; 332(1-2):4-15. PubMed ID: 23773767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy.
    Jeong A; Wong M
    Expert Rev Neurother; 2016; 16(4):437-47. PubMed ID: 26854692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.
    Galanopoulou AS; Gorter JA; Cepeda C
    Epilepsia; 2012 Jul; 53(7):1119-30. PubMed ID: 22578218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy.
    Russo E; Citraro R; Donato G; Camastra C; Iuliano R; Cuzzocrea S; Constanti A; De Sarro G
    Neuropharmacology; 2013 Jun; 69():25-36. PubMed ID: 23092918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of cell death and epileptogenesis by the mammalian target of rapamycin (mTOR): a double-edged sword?
    Zeng LH; McDaniel S; Rensing NR; Wong M
    Cell Cycle; 2010 Jun; 9(12):2281-5. PubMed ID: 20603607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model.
    Gericke B; Brandt C; Theilmann W; Welzel L; Schidlitzki A; Twele F; Kaczmarek E; Anjum M; Hillmann P; Löscher W
    Neuropharmacology; 2020 Jan; 162():107817. PubMed ID: 31654704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
    Citraro R; Leo A; Constanti A; Russo E; De Sarro G
    Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
    Jeong A; Wong M
    J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the mechanism of antiepileptogenic effect of apigenin in kainate temporal lobe epilepsy: possible role of mTOR.
    Nikbakht F; Hashemi P; Vazifekhah S; Babaei JF
    Exp Brain Res; 2023 Mar; 241(3):753-763. PubMed ID: 36719442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microglial mTOR is Neuronal Protective and Antiepileptogenic in the Pilocarpine Model of Temporal Lobe Epilepsy.
    Zhao XF; Liao Y; Alam MM; Mathur R; Feustel P; Mazurkiewicz JE; Adamo MA; Zhu XC; Huang Y
    J Neurosci; 2020 Sep; 40(40):7593-7608. PubMed ID: 32868461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials.
    Wong M
    Expert Rev Neurother; 2013 Jun; 13(6):657-69. PubMed ID: 23739003
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.